Q-omics provides the consensus-scored CASKIN1 profile across patient tissues and cancer cell-line models. CASKIN1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CASKIN1 is differentially expressed in 14, with the highest sampling consensus in UCEC. Additionally, CASKIN1 RNA expression shows 21,247 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, UCEC, and GBM as cancer lineages where CASKIN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASKIN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASKIN1 survival associations across molecular data types. CASKIN1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASKIN1 RNA expression–survival associations across cancer types. High CASKIN1 expression shows unfavorable associations in MESO, COAD, CHOL, ACC and DLBC, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for CASKIN1 RNA expression.
This table summarizes CASKIN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CASKIN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASKIN1 shows lower tumor expression in KIRC and higher tumor expression in UCEC, LUAD, LUSC, BRCA and BLCA. The UCEC box plot shows higher CASKIN1 RNA expression in tumor versus normal tissue (log2 FC = +1.746, t-test p < 0.001).
This table shows molecular features associated with CASKIN1 in patient tissues and cancer cell lines. In patient samples, CASKIN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CASKIN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
